Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab duration in ovarian cancer (BOOST)
NCT01462890Phase 3Completed
- Sponsor
- AGO Study Group
- Start
- Nov 2011
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of bevacizumab in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AGO Study Group. Started Nov 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01462890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462890.